Search research articles
Contact Us
Filters
Showing results (131-140 of 147) with videos related to
Page
of 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 9, 2012
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)
H J Meulenbeld, E D van Werkhoven, J L L M Coenen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
A Horwich, D T Sleijfer, S D Fosså, et al.
The Pharmacogenomics Journal
|
September 9, 2015
Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics
A J M Nieuweboer, M Smid, A-J M de Graan, et al.
British Journal of Cancer
|
October 13, 2012
Risk and prognostic significance of metachronous contralateral testicular germ cell tumours
M Schaapveld, A W van den Belt-Dusebout, J A Gietema, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 2, 2021
Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset
Elke Wynberg, Hugo D G van Willigen, Maartje Dijkstra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia
E Vellenga, C A Uyl-de Groot, R de Wit, et al.
International Journal of Cancer
|
August 30, 2018
Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer
T J N Hermans, C S Voskuilen, M Deelen, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2014
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
J Oldenburg, J Aparicio, J Beyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2017
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
J Bellmunt, J M Kerst, F Vázquez, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 147) with videos related to
Sort By:
Page
of 15
European Journal of Cancer (Oxford, England : 1990)
|
June 9, 2012
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)
H J Meulenbeld, E D van Werkhoven, J L L M Coenen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
A Horwich, D T Sleijfer, S D Fosså, et al.
The Pharmacogenomics Journal
|
September 9, 2015
Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics
A J M Nieuweboer, M Smid, A-J M de Graan, et al.
British Journal of Cancer
|
October 13, 2012
Risk and prognostic significance of metachronous contralateral testicular germ cell tumours
M Schaapveld, A W van den Belt-Dusebout, J A Gietema, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 2, 2021
Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset
Elke Wynberg, Hugo D G van Willigen, Maartje Dijkstra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia
E Vellenga, C A Uyl-de Groot, R de Wit, et al.
International Journal of Cancer
|
August 30, 2018
Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer
T J N Hermans, C S Voskuilen, M Deelen, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2014
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
J Oldenburg, J Aparicio, J Beyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2017
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
J Bellmunt, J M Kerst, F Vázquez, et al.
Page
of 15